ArticleCurrent oncology reports2010
Current management of hepatocellular cancer.
Article in Current oncology reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Preoperative evaluation of the histological grade of hepatocellular carcinoma with diffusion-weighted imaging: a meta-analysis.PloS one · 2015Pooled it
- Comparing a virtual reality head-mounted display to on-screen three-dimensional visualization and two-dimensional computed tomography data for training in decision making in hepatic surgery: a randomized controlled study.Surgical endoscopy · 2024Trial
- Article
- Single-cell RNA sequencing reveals the mechanism of sonodynamic therapy combined with a RAS inhibitor in the setting of hepatocellular carcinoma.Journal of nanobiotechnology · 2021Article
- Diffusion-Weighted Imaging Reflects Tumor Grading and Microvascular Invasion in Hepatocellular Carcinoma.Liver cancer · 2021Review
- Autophagic Inhibition of Caveolin-1 by CompoundFrontiers in pharmacology · 2021Article
- WIPI2 depletion inhibits the growth of hepatocellular carcinoma cells through the AMPK signaling pathway.Oncology reports · 2020Article
- Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma.Frontiers in oncology · 2020Article
- Sorafenib inhibits caspase-1 expression through suppressing TLR4/stat3/SUMO1 pathway in hepatocellular carcinoma.Cancer biology & therapy · 2018Article
- A new key player in VEGF-dependent angiogenesis in human hepatocellular carcinoma: dimethylarginine dimethylaminohydrolase 1.Angiogenesis · 2017Article
- Article
- Systems approach to characterize the metabolism of liver cancer stem cells expressing CD133.Scientific reports · 2017Article
- Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives.PloS one · 2017Article
- Article
- HCC-DETECT: a combination of nuclear, cytoplasmic, and oncofetal proteins as biomarkers for hepatocellular carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Predictors of hepatic decompensation after TACE for hepatocellular carcinoma.BMJ open gastroenterology · 2015Article
- Association of Upregulated HMGB1 and c-IAP2 Proteins With Hepatocellular Carcinoma Development and Progression.Hepatitis monthly · 2014Article
- Netrin-1 induces epithelial-mesenchymal transition and promotes hepatocellular carcinoma invasiveness.Digestive diseases and sciences · 2014Article
- Growth inhibition and apoptosis induced by 6-fluoro-3-formylchromone in hepatocellular carcinoma.BMC gastroenterology · 2014Article
- Sodium valproate induces cell senescence in human hepatocarcinoma cells.Molecules (Basel, Switzerland) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver, being the fifth most frequent cancer worldwide. It usually occurs in the setting of chronic liver disease and has a poor prognosis if untreated. Following the diagnosis, this disease requires multidisciplinary management. Orthotopic liver transplantation is theoretically the best treatment for early, unresectable HCC. However, the major practical obstacle is the extreme shortage of organs, which makes this a practical option only in selected patients. In this report we describe new advancements in diagnosis, classification, and treatment that have emerged in the field of HCC in recent years.
Indexed as
Identifiers
20425078What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.